1. The normal gastric microflora and Helicobacter pylori; before, during and after treatment with omeprazole and amoxycillin 
Inger Adamsson, Charlotta Edlund, Rein Seensalu, Svante Sjöstedt, Carl Erik Nord 
Clinical Microbiology and Infection 
Volume 4, Issue 6, Pages (June 1998)
DOI: /j tb00064.x
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Helicobacter pylori (— —) and the total number of aerobic and anaerobic microflora (— —), with mean values, in the gastric mucosa from the corpus, in patients treated with omeprazole 20 mg twice a day and placebo twice a day for 14 days. The detection limit was 102 CFU/mL. After treatment = 42 days.
Clinical Microbiology and Infection 1998 4, DOI: ( /j tb00064.x)
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Helicobacter pylori (— —) and the total numbers of aerobic and anaerobic microflora (— —), with mean values, in the gastric mucosa from the corpus, in patients treated with omeprazole 20 mg twice a day and amoxycillin 1 g twice a day for 14 days. The detection limit was 102 CFU/mL.
Clinical Microbiology and Infection 1998 4, DOI: ( /j tb00064.x)
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

4. Figure 3
AP-PCR of Helicobacter pylori strains isolated from four patients. Lanes 1-8 represent strains from patients included in the omeprazole-amoxycillin group, patients A and B. Lanes 1-4: strains from patient A, from antrum (lanes 1 and 3) and corpus (lanes 2 and 4), before (lanes 1 and 2) and after (lanes 3 and 4) treatment. Lanes 5-8: strains from patient B, from antrum (lanes 5 and 7) and corpus (lanes 6 and 8), before and after treatment. Lanes 9-15 represent strains from two patients (C and D) in the omeprazole-placebo group. Lanes 9-11: patient C, strains from antrum (lane 9) and corpus (lane 10) before treatment, and from antrum (lane 11) after treatment. Lanes 12-15: strains from antrum (lanes 12 and 14) and corpus (lanes 13 and 15), before and after treatment from patient D.
Clinical Microbiology and Infection 1998 4, DOI: ( /j tb00064.x)
Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions